TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05002192

Intervention type: DRUG
Intervention: Eucalyptol, Limonene and Pinene Enteric Soft Capsule
Description: Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP_ONLY and EXP_ONLY cohort

Intervention type: DRUG
Intervention: Eucalyptol, Limonene and Pinene Enteric Soft Capsule
Description: Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP_ONLY and EXP_ONLY cohort

Intervention type: DRUG
Intervention: Ambroxol injection
Description: Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and cohort EXP+AMB Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB_ONLY cohort Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB_ONLY cohort

Intervention type: DRUG
Intervention: Ambroxol injection
Description: Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and cohort EXP+AMB Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB_ONLY cohort Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB_ONLY cohort
Study: NCT02913573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Pectoral nerve block is a regional block administered under ultrasound guidance which blocks the nerves of the thorax and chest areas.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Description: Pectoral nerve block is a regional block administered under ultrasound guidance where 15 mL of 0.25% bupivacaine is instilled between the pectoral major and pectoral minor muscles where the lateral and medial pectoralis nerves lie. In a similar manner, 20 mL of 0.25% bupivacaine will be deposited under ultrasound-guidance at the level of the third rib above the serratus anterior muscle.
Study: NCT01726803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: The usual care intervention includes advice and education to remain active and provision of the Back Book highlighting these recommendations. Pharmaceuticals may be prescribed at the discretion of the primary care provider. Follow-up visits to primary care provided are recommended for all patients dissatisfied with their progress.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The usual care intervention includes advice and education to remain active and provision of the Back Book highlighting these recommendations. Pharmaceuticals may be prescribed at the discretion of the primary care provider. Follow-up visits to primary care provided are recommended for all patients dissatisfied with their progress.
Study: NCT05002192

Intervention type: DRUG
Intervention: Ambroxol injection
Description: Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and cohort EXP+AMB Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB_ONLY cohort Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB_ONLY cohort

Intervention type: DRUG
Intervention: Other oral mucolytic drugs
Description: Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP_ONLY and EXP_ONLY cohort

Intervention type: DRUG
Intervention: Other oral mucolytic drugs
Description: Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP_ONLY and EXP_ONLY cohort
Study: NCT03819803

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: 200 ml of a tested stool suspension of a healthy donor is instilled into the patient´s caecum or terminal ileum
Study: NCT02045277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-118 Lotion
Description: Lotion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-118 Monad HP Lotion
Description: Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-118 Monad Taz Lotion
Description: Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-118 Vehicle Lotion
Description: Vehicle
Study: NCT01703819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neurexan®
Description: 0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
Study: NCT01040780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: 125 mg three times daily (375 mg per day) by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: 250 mg every 24 hours by mouth
Study: NCT02955433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rideshare-based transportation
Study: NCT00630253

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: 30 mg/kg/day will be administered after MP on days -6, -5, -4, -3 and -2.
Study: NCT02191917

Intervention type: PROCEDURE
Intervention: Respiratory muscle strength measurements by different techniques.
Study: NCT02134314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1 Esterase Inhibitor
Description: C1 Esterase Inhibitor 50 units per kilogram intravenous infusion administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses
Study: NCT00630253

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: 30 mg/kg/day will be administered after MP on days -6, -5, -4, -3 and -2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: 30 mg/kg/day will be administered after MP on days -6, -5, -4, -3 and -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 5 mg/kg is to be given as a 2 hour infusion, Days -6 through -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 5 mg/kg is to be given as a 2 hour infusion, Days -6 through -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 5 mg/kg is to be given as a 2 hour infusion, Days -6 through -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 35 mg/m\^2 intravenously (IV) on days -6 through -2.
Study: NCT02134314

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses
Study: NCT00630253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 35 mg/m\^2 intravenously (IV) on days -6 through -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 35 mg/m\^2 intravenously (IV) on days -6 through -2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplantation
Description: Bone marrow or umbilical cord blood infusion on day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplantation
Description: Bone marrow or umbilical cord blood infusion on day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplantation
Description: Bone marrow or umbilical cord blood infusion on day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone (MP) 2 mg/kg/day intravenously every 24 hours will be given from day -6 until day -2 as a premedication for ATG.
Study: NCT02906683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-303
Description: Oral administration for 8 weeks, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-303
Description: Oral administration for 8 weeks, once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration for 8 weeks, once daily.
Study: NCT00630253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone (MP) 2 mg/kg/day intravenously every 24 hours will be given from day -6 until day -2 as a premedication for ATG.
Study: NCT00859898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 10 mg, once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 10 mg, once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: Tablets, Oral, up to 2000 mg, once daily, 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR
Description: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks
Study: NCT00630253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone (MP) 2 mg/kg/day intravenously every 24 hours will be given from day -6 until day -2 as a premedication for ATG.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 mcg/kg per day intravenously (IV) continue until Absolute neutrophil count \> or = 2.5 x 10\^9/L
Study: NCT00859898

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapagliflozin matching Placebo
Description: Tablets
Study: NCT00630253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 mcg/kg per day intravenously (IV) continue until Absolute neutrophil count \> or = 2.5 x 10\^9/L

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 mcg/kg per day intravenously (IV) continue until Absolute neutrophil count \> or = 2.5 x 10\^9/L

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine IV over 2 hours or orally every 8-12 hours beginning on day -3 and continuing until day 100, followed by a taper.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine IV over 2 hours or orally every 8-12 hours beginning on day -3 and continuing until day 100, followed by a taper.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine IV over 2 hours or orally every 8-12 hours beginning on day -3 and continuing until day 100, followed by a taper.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute GVHD. Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count \[ANC\] \> 0.5 x 10\^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours PO (to a maximum dose of 1 gram).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute GVHD. Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count \[ANC\] \> 0.5 x 10\^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours PO (to a maximum dose of 1 gram).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute GVHD. Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count \[ANC\] \> 0.5 x 10\^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours PO (to a maximum dose of 1 gram).
Study: NCT01015963

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Perform DNA sample analysis
Study: NCT02186353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partial feeding study
Description: Provision of all grain foods where only the processing of kernels used to produce the grain foods will differ among test diets. Each participant will be assigned to complete the three 4-week test diets in random sequence.
Study: NCT00859898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin HCl Modified Release matching Placebo
Description: Tablets
Study: NCT01819922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157
Description: 600 mg as powder in capsule, one dose within 5 minutes prior to AM meal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo powder in capsule, one dose within 5 minutes prior to AM meal
Study: NCT03010423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorandil
Description: Participants received Nicorandil 5 milligram (mg) tablet, three times a day for 12 weeks.
Study: NCT03048721

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin Tape Stripping
Description: For psoriasis group, tape-stripping will be done in both involved and uninvolved skin. The tape-stripping will be performed within 2.5 cm of the first punch biopsy. For healthy control group, tape-stripping will be performed on normal skin, within 2.5. cm of the first punch biopsy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin Tape Stripping
Description: For psoriasis group, tape-stripping will be done in both involved and uninvolved skin. The tape-stripping will be performed within 2.5 cm of the first punch biopsy. For healthy control group, tape-stripping will be performed on normal skin, within 2.5. cm of the first punch biopsy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Punch Biopsy
Description: For psoriasis group, one punch biopsy will be taken from each of the following areas: involved skin, tape-stripped involved skin, uninvolved skin, and tape-stripped uninvolved skin. For healthy control group, one punch biopsy will be taken from each of the following areas: normal skin and tape-stripped normal skin (within 2.5 cm of the first punch biopsy).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Punch Biopsy
Description: For psoriasis group, one punch biopsy will be taken from each of the following areas: involved skin, tape-stripped involved skin, uninvolved skin, and tape-stripped uninvolved skin. For healthy control group, one punch biopsy will be taken from each of the following areas: normal skin and tape-stripped normal skin (within 2.5 cm of the first punch biopsy).
Study: NCT04241237

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood will be drawn from each patient to check the concordance between liquid and tissue biopsy
Study: NCT03769740

Intervention type: DEVICE
Intervention: Cerebral Oximetry
Description: Non invasive, near infrared spectroscopy cerebral oximetry
Study: NCT04230486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cross-model Visual Auditory Rehabilitation
Description: Subjects will put on a virtual reality rehabilitation system which will present sights and sounds.
Study: NCT01148056

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: Radiation therapy once a day for 5 days
Study: NCT02926573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02186353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partial feeding study
Description: Provision of all grain foods where only the processing of kernels used to produce the grain foods will differ among test diets. Each participant will be assigned to complete the three 4-week test diets in random sequence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Partial feeding study
Description: Provision of all grain foods where only the processing of kernels used to produce the grain foods will differ among test diets. Each participant will be assigned to complete the three 4-week test diets in random sequence.
Study: NCT03143049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCD
Description: For PCD, patients will be treated as follows: PO pomalidomide 4mg from D1-21, PO cyclophosphamide 400mg on D1, 8 and 15, and PO or IV dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.~Patients will be assessed every 28 days (+/- 10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD
Description: For PD, Patients will be treated as follows: PO pomalidomide 4mg from D1-21 and PO or IV dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.~Patients will be assessed every 28 days (+/- 10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first).
Study: NCT00414726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NBO (Normobaric Oxygen)
Description: High-flow oxygen delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NBO (Normobaric Oxygen)
Description: High-flow oxygen delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
Study: NCT02229903

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active DTMS Treatment
Description: H-coil Deep TMS 29 TMS treatments over 6 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: 29 treatments over 6 weeks.
Study: NCT02079285

Intervention type: PROCEDURE
Intervention: EUS-FNA
Study: NCT03373513

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic single-site Hysterectomy
Description: Robotic assisted Periumbilical single incision hysterectomy
Study: NCT00414726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Room Air
Description: Room Air delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Room Air
Description: Room Air delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
Study: NCT00085501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: Arm 1: 400 mg/m2 (Initial dose), 2 hour IV infusion on Day 1, Week 1 only. 250 mg/m2 (Subsequent doses), 1 hour IV infusion, on Day 1 weekly starting at Week 2.~Arm 2: 400 mg/m2 (Initial dose), 2 hour IV infusion on Week 13 ONLY 250 mg/m2 (Subsequent doses), 1 hour IV infusion, weekly starting at Week 14.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: Arm 1: 400 mg/m2 (Initial dose), 2 hour IV infusion on Day 1, Week 1 only. 250 mg/m2 (Subsequent doses), 1 hour IV infusion, on Day 1 weekly starting at Week 2.~Arm 2: 400 mg/m2 (Initial dose), 2 hour IV infusion on Week 13 ONLY 250 mg/m2 (Subsequent doses), 1 hour IV infusion, weekly starting at Week 14.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Arm 1: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 2~Arm 2: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Arm 1: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 2~Arm 2: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Arm 1: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 4.~Arm 2: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 1.
Study: NCT01598584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine plus gemcitabine
Description: Mirtazapine,15mg/day for 3 days, If patients is durable, the dosage increase to 30mg/day, if the patient is durable, the doctor then will decided whether to increase to 45mg. Gemcitabine 1000mg/M2,d1,d8,q3w

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine, placebo
Description: Gemcitabine 1.0g/m2,d1,d8,q3w placebo
Study: NCT00085501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Arm 1: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 4.~Arm 2: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 1.
Study: NCT03373513

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic hysterectomy
Description: Multiport laparoscopic hysterectomy
Study: NCT00185614

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic cell transplant (Auto-HCT)
Description: The target cell dose is 2.6 x 10e6 CD34+ cells/kg

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplant (Allo-HCT)
Description: The target cell dose is 5 x 10e6 CD34 cells/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide administered intravenously (IV) at 4 mg /m² mobilize peripheral blood progenitor cells (PBPC) for autologous re-infusion
Study: NCT00372996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-751,871
Description: CP-751,871 given at 20 mg/kg IV on day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Exemestane given at 25 mg orally once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exemestane
Description: Exemestane given at 25 mg orally once a day. Treatment until progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Used for salvage therapy and administered according to the local label and standard clinical practice.
Study: NCT00185614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: * Filgrastim 10 µg/kg/day to mobilize peripheral blood progenitor cells (PBPC) for autologous re-infusion (Auto-HCT)~* Filgrastim 5 µg/kg/day starting 6 days after melphalan (Day 4 after Auto-HCT)~* Filgrastim 16 µg/kg/day to mobilize donor peripheral blood progenitor cells (PBPC) for allogeneic transplant (Allo-HCT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 200 mg/m2 (high-dose) intravenously as conditioning for Auto-HCT